| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2036.2000.00856.X |
| P698 | PubMed publication ID | 11012468 |
| P50 | author | Gary W. Falk | Q37834710 |
| P2093 | author name string | P J Kahrilas | |
| D W Collins | |||
| D A Johnson | |||
| C Schmitt | |||
| B Hamelin | |||
| D D'Amico | |||
| B Joelsson | |||
| J Whipple | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | omeprazole | Q422210 |
| esomeprazole | Q553223 | ||
| randomized controlled trial | Q1436668 | ||
| P304 | page(s) | 1249-1258 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators | |
| P478 | volume | 14 |
| Q83989365 | A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis |
| Q83208440 | A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis |
| Q34174536 | A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole |
| Q37160360 | A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). |
| Q35745058 | A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials |
| Q35577787 | An Overview of Proton Pump Inhibitors |
| Q35745038 | Assessment of reflux symptom severity: methodological options and their attributes |
| Q51651359 | Atypical Manifestations of Gastro-Oesophageal Reflux |
| Q64084464 | Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial |
| Q37106395 | Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. |
| Q34509642 | Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor |
| Q35603768 | Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know |
| Q42283418 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
| Q40316973 | Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch. |
| Q52945054 | Comparison of inter- and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists. |
| Q43957394 | Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. |
| Q26827673 | Current perspectives in NSAID-induced gastropathy |
| Q41246716 | Deracemization of a Racemic Allylic Sulfoxide Using Viedma Ripening. |
| Q28474985 | Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review |
| Q35216881 | Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease |
| Q34340193 | Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole |
| Q34370499 | Dyspepsia: challenges in diagnosis and selection of treatment |
| Q45004669 | Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment |
| Q34523308 | Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease |
| Q46596548 | Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study |
| Q44485391 | Effects of 6-12 months of esomeprazole treatment on the gastric mucosa |
| Q35987201 | Efficacy of esomeprazole in treating acid-related diseases in Japanese populations |
| Q35149874 | Endoscopic therapy for gastroesophageal reflux disease: what have we learned and what needs to be done? |
| Q34030127 | Esomeprazole |
| Q45045271 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms |
| Q44581543 | Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing |
| Q33601940 | Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study |
| Q44654789 | Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis |
| Q35010994 | Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis |
| Q34716982 | Esomeprazole: a review of its use in the management of acid-related disorders |
| Q34621465 | Esomeprazole: a review of its use in the management of acid-related disorders in the US. |
| Q37032564 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults |
| Q39412138 | Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis |
| Q80059887 | Failures in a proton pump inhibitor therapeutic substitution program: lessons learned |
| Q47110692 | First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease |
| Q42110833 | Gastro-oesophageal reflux disease: symptoms, erosions, and Barrett's--what is the interplay? |
| Q34775943 | Guide to the use of proton pump inhibitors in adult patients |
| Q41560226 | Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis |
| Q36334704 | Healing of oesophagitis |
| Q80154601 | Heartburn severity does not predict disease severity in patients with erosive esophagitis |
| Q35549779 | Improving Health-Related Quality of Life in Gastro-Oesophageal Reflux Disease |
| Q34735634 | Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits |
| Q35597419 | Long term failure of endoscopic gastroplication (EndoCinch). |
| Q37784374 | Maintenance Treatment With Proton Pump Inhibitors for Reflux Esophagitis in Pediatric Patients: A Systematic Literature Analysis |
| Q37808356 | Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole |
| Q37260543 | Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole |
| Q35203132 | Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease |
| Q24234225 | Medical treatments in the short term management of reflux oesophagitis |
| Q24245220 | Medical treatments in the short term management of reflux oesophagitis |
| Q43854731 | Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials |
| Q39390621 | Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms |
| Q43507064 | One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients |
| Q44465351 | One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection |
| Q44596961 | Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects |
| Q35149823 | Overview of medical therapy for gastroesophageal disease |
| Q41710021 | Payments, promotion, and the purple pill |
| Q34320782 | Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole |
| Q74404039 | Pharmacologic Management of Gastroesophageal Reflux Disease |
| Q34637403 | Pharmacologic management of gastroesophageal reflux disease |
| Q24634771 | Pharmacology of proton pump inhibitors |
| Q35597478 | Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study |
| Q35074278 | Proton pump inhibitor for non-erosive reflux disease: a meta-analysis |
| Q35167717 | Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety |
| Q35010979 | Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. |
| Q43946238 | Rabeprazole: quest for the best PPI. |
| Q35076651 | Reflux disease management strategy: initial therapy |
| Q35026352 | Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease |
| Q36478873 | Review article: acid-related disease--what are the unmet clinical needs? |
| Q35076648 | Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis |
| Q35076644 | Review article: initial therapy of reflux disease with esomeprazole |
| Q35145033 | Review article: management of mild and severe gastro-oesophageal reflux disease |
| Q33423526 | Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis |
| Q35744422 | Single-enantiomer drugs: elegant science, disappointing effects |
| Q35744418 | Single-isomer drugs: true therapeutic advances |
| Q37136970 | Stereoselective disposition of proton pump inhibitors |
| Q35745029 | Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs |
| Q39395211 | Symptom-relieving Effect of Esomeprazole 40 mg Daily in Patients with Heartburn |
| Q33695532 | The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study |
| Q37187264 | The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor |
| Q24791577 | The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole |
| Q35039109 | The use of proton pump inhibitors in children: a comprehensive review |
| Q46723156 | The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications |
| Q36204260 | Treatment of uncomplicated reflux disease |
| Q77632117 | [Clinical practice guideline on the management of patients with gastroesophageal reflux disease (GERD)] |
| Q81380016 | [Reflux esophagitis] |
| Q80606073 | [Therapeutic strategies in non-erosive gastro-oesophageal reflux disease] |
Search more.